Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Jun;52(3):858–862. doi: 10.1128/iai.52.3.858-862.1986

A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.

L L Simpson
PMCID: PMC260939  PMID: 3011675

Abstract

4-Aminopyridine and 3,4-diaminopyridine were evaluated for their abilities to delay the onset of paralysis due to botulinum neurotoxin types A, B, and E. Experiments were done on phrenic nerve-hemidiaphragm preparations excised from mice. At a concentration that produced an enhancement in muscle twitch amplitude, 4-aminopyridine and 3,4-diaminopyridine delayed the onset of paralysis due to botulinum toxin type A. Under the same conditions, the drugs did little to protect tissues against botulinum toxin types B and E. 3,4-Diaminopyridine was also evaluated for its ability to reverse the paralysis due to botulinum toxin. Experiments were done on rat phrenic nerve-hemidiaphragm preparations that had previously been poisoned in vivo. The drug produced transient increases in neuromuscular transmission, with the effect being greater for botulinum neurotoxin type A than for botulinum neurotoxin types B and E. Equivalent types of experiments were done with tetanus toxin. The results with 3,4-diaminopyridine showed that tetanus toxin resembled botulinum toxin types B and E. The data help to clarify the role of aminopyridines as therapeutic agents in the treatment of botulism. They also provide insights into the mechanism of action of clostridial neurotoxins.

Full text

PDF
858

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dreyer F., Schmitt A. Different effects of botulinum A toxin and tetanus toxin on the transmitter releasing process at the mammalian neuromuscular junction. Neurosci Lett. 1981 Nov 4;26(3):307–311. doi: 10.1016/0304-3940(81)90150-6. [DOI] [PubMed] [Google Scholar]
  2. Gundersen C. B. The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog Neurobiol. 1980;14(2-3):99–119. doi: 10.1016/0301-0082(80)90019-2. [DOI] [PubMed] [Google Scholar]
  3. Habermann E., Dreyer F., Bigalke H. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol. 1980 Feb;311(1):33–40. doi: 10.1007/BF00500299. [DOI] [PubMed] [Google Scholar]
  4. Katz B., Miledi R. Estimates of quantal content during 'chemical potentiation' of transmitter release. Proc R Soc Lond B Biol Sci. 1979 Aug 31;205(1160):369–378. doi: 10.1098/rspb.1979.0070. [DOI] [PubMed] [Google Scholar]
  5. Kauffman J. A., Way J. F., Jr, Siegel L. S., Sellin L. C. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol. 1985 Jun 30;79(2):211–217. doi: 10.1016/0041-008x(85)90342-4. [DOI] [PubMed] [Google Scholar]
  6. Kozaki S. Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jul;308(1):67–70. doi: 10.1007/BF00499721. [DOI] [PubMed] [Google Scholar]
  7. Lundh H., Leander S., Thesleff S. Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine. J Neurol Sci. 1977 May;32(1):29–43. doi: 10.1016/0022-510x(77)90037-5. [DOI] [PubMed] [Google Scholar]
  8. Lundh H., Thesleff S. The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur J Pharmacol. 1977 Apr 21;42(4):411–412. doi: 10.1016/0014-2999(77)90176-5. [DOI] [PubMed] [Google Scholar]
  9. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther. 1982;19(2):165–194. doi: 10.1016/0163-7258(82)90061-4. [DOI] [PubMed] [Google Scholar]
  10. Schmitt A., Dreyer F., John C. At least three sequential steps are involved in the tetanus toxin-induced block of neuromuscular transmission. Naunyn Schmiedebergs Arch Pharmacol. 1981;317(4):326–330. doi: 10.1007/BF00501314. [DOI] [PubMed] [Google Scholar]
  11. Sellin L. C., Thesleff S., Dasgupta B. R. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol Scand. 1983;119(2):127–133. doi: 10.1111/j.1748-1716.1983.tb07317.x. [DOI] [PubMed] [Google Scholar]
  12. Simpson L. L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J Pharmacol Exp Ther. 1983 Jun;225(3):546–552. [PubMed] [Google Scholar]
  13. Simpson L. L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther. 1980 Jan;212(1):16–21. [PubMed] [Google Scholar]
  14. Simpson L. L. Pharmacological studies on the subcellular site of action of botulinum toxin type A. J Pharmacol Exp Ther. 1978 Sep;206(3):661–669. [PubMed] [Google Scholar]
  15. Simpson L. L. The interaction between aminoquinolines and presynaptically acting neurotoxins. J Pharmacol Exp Ther. 1982 Jul;222(1):43–48. [PubMed] [Google Scholar]
  16. Simpson L. L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981 Sep;33(3):155–188. [PubMed] [Google Scholar]
  17. Thomsen R. H., Wilson D. F. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther. 1983 Oct;227(1):260–265. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES